luveltamab tazevibulin
luveltamab tazevibulin: sourced relationships with 1 company · 6 clinical trials tracked.
luveltamab tazevibulin evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could luveltamab tazevibulin → STRO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| SUTRO BIOPHARMA, INC. (STRO) | Phase 2 |
| SUTRO BIOPHARMA, INC. (STRO) Head & Neck Squamous Cell Carcinoma | Phase 2 |
Clinical Trial Registry Records (6)
A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)
Primary endpoint: Evaluate efficacy of luveltamab tazevibulin monotherapy
A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects With Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1
Primary endpoint: Objective Response Rate (ORR)
A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy of STRO-002 in Chinese Adults With Advanced Epithelial Ovarian Cancer, Endometrial Cancer, and Other Advanced Malignant Solid Tumors.
Primary endpoint: DLT Assessment
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
Primary endpoint: Progression Free Survival (PFS)
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
Primary endpoint: Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Primary endpoint: Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)
Frequently asked questions
Which companies have sourced relationships with luveltamab tazevibulin?
luveltamab tazevibulin has dated SEC/FDA relationship records for SUTRO BIOPHARMA, INC..
How many clinical trials involve luveltamab tazevibulin?
BioSniper tracks 6 clinical trials involving luveltamab tazevibulin.